Introduction
In 1982 Lewis et al. [47] described five patients with a neurological disorder characterised by gradually evolving weakness and sensory loss, attributable to focal involvement of individual nerves. Electrophysiological examination of these patients revealed multifocal motor conduction blocks and in subsequent sural nerve biopsy specimens demyelination was observed. It was concluded that this multifocal neuropathy was a variant of chronic acquired demyelinating polyneuropathy. In later reports multifocal motor conduction blocks were described in patients with a similar clinical picture, who were initially diagnosed as having the lower motor neuron form of motor neuron disease [58, 62] . These patients had increased titres of antibodies directed against GM1 gangliosides, suggesting that the disorder might be immune-mediated. Moreover, treatment of these patients with cyclophosphamide was followed by a marked improvement of strength [62] .
During the past decade several lower motor neuron syndromes have been identified that can be distinguished from motor neuron disease [63] . Unlike the latter, these syndromes appear to be immune-mediated and treatable. The present paper reviews the literature on a rare, treatable motor neuropathy which is characterised by slowly progressive asymmetrical muscle weakness and persistent motor conduction blocks. This neurological entity, which Abstract We present a review of the literature on multifocal motor neuropathy (MMN), a rare neurological disorder which has features in common with both chronic inflammatory demyelinating neuropathy and lower motor neuron disease. Clinically, MMN is characterised by slowly progressive asymmetrical limb weakness, usually most prominent in the forearms. Weakness may be associated with muscle wasting, fasciculations and decreased tendon reflexes. Serum anti-GM1 ganglioside antibody titres may be increased. The diagnostic hallmark of MMN is the electrophysiological demonstration of persistent localised motor conduction blocks, with otherwise normal or near-normal motor and sensory conduction velocities. The pathogenesis of MMN has not been elucidated completely. There is, however, substantial evidence for an autoimmune mechanism. Based on the possible involvement of the immune system in the pathogenesis of MMN the therapeutic efficacy of several immunomodulatory drugs has been tested. Treatment of MMN patients with human immunoglobulin or cyclophosphamide is usually followed by a marked improvement of strength. The finding that MMN is a potentially treatable disorder underscores the importance of distinguishing MMN from lower motor neuron disease, for which no effective therapy is currently available.
Progressive weakness and muscular atrophy are the clinical hallmarks of MMN. The weakness characteristically shows an asymmetrical pattern of distribution and affected muscles are usually confined to the territory of individual nerves [13, 59, 85] . Weakness is more prominent in the arms than in the legs, and is most pronounced in distal muscles [9, 52, 63] . Muscular atrophy may be substantial [9, 39] , but can be absent despite severe weakness [39, 82] . Other motor symptoms of MMN include muscle cramps and fasciculations in weak muscles [5, 9, 39, 44, 58] . Tendon reflexes are usually reduced in affected regions [5, 13, 52, 63] , but may occasionally be brisk in the arms [39, 58] . The muscles innervated by the cranial nerves are rarely involved [24, 34] . According to some authors, minor sensory symptoms and signs, such as complaints of paraesthesia or numbness or mild distal sensory loss, may be consistent with the diagnosis of MMN [13, 39, 52, 81] .
The onset of MMN is usually between the third and the fifth decade of life. It appears to be more common in men [13, 39, 63] . If untreated, it runs a slowly progressive, sometimes stepwise course. Spontaneous remission has occasionally been reported [11] . Now that the awareness of the diagnosis of MMN among physicians is increasing, patients with a disease duration of over 15 years have been identified [9, 13, 39, 45, 63] . In these patients weakness usually still affects a limited number of muscles and remains confined to the limbs. Occasionally, progression of weakness may lead to wheel-chair dependency [68, 82] .
As mentioned in the introduction, LMND [12, 42, 94] and the pure motor form of CIDP [3, 6, 25, 48] are the two main differential diagnoses of MMN. The characteristics that enable the differentiation of MMN from LMND and CIDP are discussed in subsequent paragraphs of this paper and summarised in Table 2 . The differential diagnosis of MMN further includes other lower motor neuron syndromes, such as hereditary neuropathies and neuropathies associated with porphyria or lead intoxication [33, 49, 78] . Hereditary neuropathies that show similarities with MMN include type II hereditary motor and sensory neuropathy (HMSN) [78] and various subtypes of proximal or distal hereditary motor neuropathies (HMNs) (classification of Harding [33] ). Apart from the clues provided by the occurrence of neuropathy in other family members, 144 [33] . The acquired neuropathies associated with porphyria or lead intoxication can be distinguished from MMN based on some neurological and non-neurological accompanying features. Neuropathy associated with porphyria is predominantly motor, and mainly affects the upper limbs and occasionally the cranial nerves. Accompanying features may include confusion, convulsions, involvement of the autonomic system and abdominal pain. Porphobilinogen can be detected in urine samples. Porphyric neuropathy usually develops within days, which, in addition to the accompanying non-neuropathic features, distinguishes it from MMN (for review, see [92] ). Neuropathy associated with lead intoxication mainly affects the arms. Lead-induced neuropathy can be distinguished from MMN based on accompanying features of lead poisoning, such as anaemia and alimentary symptoms. The diagnosis of lead-induced neuropathy can be confirmed by the demonstration of elevated blood lead level, or by the examination of urine samples following a chelation challenge [78] .
Laboratory investigations

Blood and CSF tests
Routine analysis of blood and urine is unremarkable in MMN patients. Protein electrophoresis and immunoelectrophoresis usually do not show monoclonal proteins [9, 13, 40, 82] . The CSF protein level is normal or sometimes slightly increased up to 70 mg/dl [13, 35, 39, 58] . This feature can be critical in the distinction of MMN from CIDP, in which protein levels are usually elevated [3, 6, 25, 48] . Oligoclonal bands are not found in the CSF and the IgG index is normal.
Anti-GM1 ganglioside antibodies
Initial reports on increased titres of anti-GM1 ganglioside IgM antibodies in monoclonal or polyclonal form in lower motor neuron syndromes have raised hope for the identification of a specific diagnostic marker for MMN [60, 61, 63] . Pestronk et al. [63] found increased anti-GM1 IgM titres in 21 of 25 patients with a lower motor neuron syndrome with conduction blocks, a diagnosis that may be consistent with MMN. High anti-GM1 IgM titres were also found in 18 of 28 patients with a lower motor neuron syndrome without conduction block, whereas high titres were not detected in a group of 24 patients with CIDP. In [13, 27, 45, 76, 85] later reports however, the specificity of anti-GM1 antibodies for MMN or other lower motor neuron syndromes has been questioned [57, 74, 78] . Anti-GM1 titres have now been demonstrated in a variety of sensorimotor neuropathies [8, 38, 51, 69, 83, 90] , primary lateral sclerosis and amyotrophic lateral sclerosis [1, 51, 76] , in non-neurological auto-immune diseases [61] and also in healthy subjects [1, 69, 83] . Only very high titres may be specific for lower motor neuron syndromes [16, 32, 38, 51, 60, 69] . The definition of "high titres" varies in the literature [60, 78, 91] . Part of this variation may well be related to variations in the ELISA procedure, which is used to determine antibody titres. A recent meta-analysis concluded that the ELISA is a useful diagnostic test to demonstrate anti-GM1 antibodies, provided that the ELISA protocol applied includes incubation of serum overnight and that no detergent is used [91] . Moreover, the upper limit of "normal titres" should be established for individual laboratories.
In general, the demonstration of high anti-GM1 antibody titres in a patient with progressive weakness is suggestive of a diagnosis of MMN or LMND, and should prompt extensive electrophysiological examination.
Electrophysiological investigations
The electrophysiological hallmark of MMN is motor conduction block (MCB). MCB is the failure of propagation of a nerve action potential across a segment of a myelinated motor fibre, of which the axon is intact. MCB in a certain segment of the nerve leads to reduction of the amplitude and the area of the compound muscle action potential (CMAP) after stimulation of the nerve proximal to this segment, whereas the CMAP is normal after stimulation distal to this segment. In MMN MCB is most frequently detected in the median and ulnar nerves -proximal as well as distal. Conduction abnormalities across the site of MCB can be localised to 35-100 mm segments [14, 39, 52, 68] . It should be noted, however, that MCB is not specific for MMN. MCBs have been demonstrated in acute and chronic compressive neuropathies, GuillainBarré syndrome and CIDP [3, 68, 79] .
Outside the sites of MCB, nerve conduction velocities are usually normal, although some patients may show mild features of multifocal demyelination, such as temporal dispersion and segmental reductions in nerve conduction velocity elsewhere [14] . Sensory conduction velocities are usually normal or only slightly reduced throughout the peripheral nerves and, surprisingly, across the segments of MCB as well [14, 39, 58] . F-wave latencies can be prolonged [13, 14, 30, 62] , even in nerves without detectable MCBs or motor nerve conduction slowing [9, 14] . The EMG shows evidence of axonal degeneration, with fibrillation potentials and positive sharp waves in atrophic weak muscles, whereas such activity is rare in other muscles [39, 58, 62] .
There are several difficulties associated with the identification of MCBs [21, 59, 74, 79] . MCB is suspected when the amplitude and area of the CMAP after proximal stimulation of a nerve is reduced compared with the CMAP evoked after distal stimulation. However, other factors, such as temporal dispersion and the associated phase cancellation, may also lead to reductions in CMAP amplitude after proximal compared to distal stimulation. The critical point in identifying MCBs is to determine whether a reduction of CMAP amplitude and/or area is due to MCB, temporal dispersion or both. The minimal extent of CMAP amplitude and area reductions necessary to identify a MCB ranges from 20% to 60% in different studies [21, 50] . It is noteworthy that area reductions up to 25-30% have been described in healthy controls [55] , indicating that a reduction of the CMAP amplitude and area less than 30% definitely lacks specificity for MCB. Interestingly, computer model studies have indicated that reduction of CMAP area of more than 50% points to MCB in at least some fibres, independent of the distance over which conduction is measured [66] . Hence, the electrophysiological demonstration of CMAP area reductions of at least 50% is highly suggestive of MCB and hence might be labelled "definitive MCB". In cases of reduction of the CMAP amplitude of less than 50%, but more than 30% for arm nerves, or 40% for lower limb nerves, it may be more appropriate to speak of "possible MCB". Evidence of MCB should subsequently be obtained by determining whether the reduction in amplitude can be attributed to short nerve segments, thereby largely eliminating the effect of temporal dispersion [21, 43] . In that case an amplitude reduction of more than 30% can also be labelled "definitive MCB" [28] .
Thus far the exact mechanism underlying the MCBs in MMN remains unclear. MCB has been attributed to demyelination of one or several adjacent internodes [29, 36] . Evidence for a role of demyelination in MCB in MMN is provided by a recent study [29] . In animals with demyelinating neuropathy MCB can be induced by small increments of temperature within the physiological range [65] . Alternatively, in demyelinated fibres MCB can be relieved by cooling of the nerve [65, 72] . In patients with MMN, MCB was also partially relieved after cooling of nerves to 25°C, suggesting that in MMN at least part of the MCB is caused by demyelination [29] . In addition to demyelination, MCB may involve blocking of sodium or potassium channels at the nodal or paranodal region of peripheral nerves by antibodies [70, 75] . In a recent study it was shown in vitro that anti-GM1 antibodies may have two distinct effects on nodal membrane properties [75] . One, independent of complement, is an increase in the potassium current. The other, in the presence of complement, is a decrease in the sodium current, in association with increased membrane leakiness, which may be due to the formation of antibody-complement complexes. It was suggested that the observed changes in sodium and potassium conductance may be involved in the conduction block observed in peripheral nerve in vivo.
An interesting feature of MMN is the long-term persistence (up to 3 years) of MCBs at the same site [43] . This is unusual, since experimental and clinical studies have shown that demyelinative conduction block is generally completely reversible within a few weeks as the nerve segment remyelinates [74] . Irreversibility of MCB in MMN is hypothesised to be caused by ongoing breakdown of myelin as a result of impairment of the blood-nerve barrier [36] . Alternatively, antibodies bound to demyelinated axons may inhibit remyelination or block the sodium channels at the nodes of Ranvier thus leading to persistent MCB [13, 36, 75] .
Pathological findings
Nerve biopsies
Several patients with MMN have had a biopsy of a sensory nerve. Out of eight patients who had a sural nerve biopsy, three nerve specimens showed no pathological abnormalities [39, 52, 58, 82] . In the remaining five perivascular inflammation was demonstrated in two, demyelination in two and reduced myelinated fibre density in five. Only one of these eight patients had minor sensory symptoms and signs [39] . In 12 MMN patients the cutaneous branch of the radial nerve was biopsied for morphological examination. Out of these 12 biopsy specimens, five showed no pathological abnormalities, four showed clusters of regenerating fibres, two showed demyelination and in one axonal lesions were observed, in association with regenerating clusters [9] . The significance of morphological abnormalities in sensory nerves, in a predominantly motor neuropathy such as MMN, remains to be determined. These findings do, however, suggest that sensory nerves may be involved in MMN.
In addition to sensory nerves, nerves containing both motor and sensory fibres have been examined. Kaji et al. [35] demonstrated focal enlargement of nerves at the site of MCBs by means of magnetic resonance imaging in two MMN patients. In one patient the site of the enlargement in the brachial plexus was explored surgically. During surgery CMAPs were recorded, demonstrating MCB across the enlarged segment. A biopsy was taken from the medial pectoral nerve, just distal of the enlargement. Morphological findings in the biopsy specimen were oedema, demyelination and "onion-bulb" formation. Intra-axonal degeneration of mitochondria and other organelles suggested axonal involvement. Auer et al. [4] performed a proximal ulnar nerve biopsy in a patient with a six year history of weakness and wasting in the upper limbs, which started in the muscles innervated by the ulnar nerve. MCB was demonstrated in the brachial plexus. Light microscopy of cross-sections showed patches of thinly myelinated large axons and onion-bulb formations. Axonal loss was minimal and there were no signs of inflammation. Unfortunately the specific site of the biopsy was not examined electrophysiologically.
Autopsy findings
Two reports of autopsy findings in patients with a possible diagnosis of MMN have been published thus far [2, 56] . In the first patient [2] weakness progressed to a stage of tetraplegia 5 years after onset, followed by weakness of the respiratory muscles, which is highly unusual for MMN. MCBs were demonstrated in the right brachial plexus, which was compatible with the diagnosis of MMN. The patient died 4 months later. Unfortunately the cause of death was not specified. Pathological findings at autopsy were severe axon depletion with loss of myelin and a reactive proliferation of Schwann cells in the sciatic and peroneal nerves. The site of MCB was not examined. There was loss of anterior root fibres and in the spinal cord there was severe loss of anterior horn motor neurons, most pronounced in the lower segments. Upper motor neuron lesions were not observed and the cranial nerve motor nuclei were intact.
In the second patient [56] , after an initial slowly progressive course of 5 years, rapid deterioration led to walking and breathing difficulties. Mild sensory loss was noted and the tendon reflexes were brisk. Initially the patient was thought to have MND. Electrophysiological examination showed marked reductions in motor and sensory conduction velocities and MCBs in the tibial, peroneal and median nerves, precluding the diagnosis of MND. In a sural nerve biopsy specimen a decrease in the number of myelinated fibres, clusters of regenerating fibres and demyelination were observed. The patient was diagnosed as having MMN, although the widespread sensorimotor conduction abnormalities were atypical, and the diagnosis of CIDP might have been considered. Subsequent treatment with prednisone was without apparent effect, and the patient died of respiratory failure. Pathological analysis of the anterior roots at autopsy showed demyelination, IgM and IgG deposits, and infiltration of mononuclear inflammatory cells. In the spinal cord a reduction of anterior horn cells was observed, most pronounced in the cervical and lumbosacral regions. The lateral corticospinal tracts were normal. Again the sites of MCB were not examined.
The question remains whether these cases are in fact representative for MMN. If so, the anterior horn cell loss, which was demonstrated in both patients, may be an important factor in the prognosis and treatment perspectives of MMN.
Pathogenesis
The pathogenesis of MMN remains unclear, although evidence for an autoimmune mechanism is substantial. Histological studies have shown inflammatory demyelination, antibodies to nerve gangliosides have been demonstrated and patients show a favourable response to immunosuppressive therapy [27, 62, 76] .
In studies on the pathogenesis of MMN, the possible role of anti-GM1 ganglioside antibodies has been scrutinised [41, 60, 73] . Gangliosides are naturally occurring glycosphingolipids, which constitute important components of mammalian cell membranes. Gangliosides, in particular GM1, are particularly abundant in neuronal membranes and peripheral nerve myelin. However, GM1 is exposed to the cell surface only at the paranodal region and at the presynaptic nerve ending [18, 19, 77] . Since IgM antibodies to GM1 can be detected in normal serum [1, 69, 83] they are considered as non-pathogenic under normal circumstances. In contrast, under pathological circumstances, leading to an increase in antibody concentration or affinity, anti-GM1 antibodies could be pathogenic [78] . A role for anti-GM1 antibodies in the aetiology of MCB was suggested by the demonstration of IgM antibody deposits at the nodes of Ranvier in a patient with progressive weakness, MCBs and increased anti-GM1 antibody titres [70] . When serum of this patient was injected into rat sciatic nerve, IgM bound to the nodes of Ranvier. Moreover, in rats intraneural injection of serum from anti-GM1 antibody-positive MMN patients produced electrophysiological findings suggestive of MCB and demyelination [71, 80] . Surprisingly, serum of patients with LMND did not show specific antibody binding and failed to induce MCB [80] . In mice it was recently demonstrated that repeated intraperitoneal injection of plasma from anti-GM1 antibody-positive (as well as negative) MMN patients induced MCB [67] . This interesting finding suggests the involvement of antibodies other than anti-GM1 antibodies, or other humoral factors, with similar actions to anti-GM1 in the development of MCB. These are perhaps directed to other glycoproteins, or GM1 isotypes that were not detected in the ELISA in this study.
An intriguing feature of MMN that might be explained by GM1 distribution is the preferential involvement of motor fibres. Although myelin of motor and sensory fibres appears to be similar, different composition of GM1 in motor and sensory fibres may affect antibody binding [36, 54] . Different ceramide composition of GM1 in human motor and sensory nerves has indeed been demonstrated [53] . Moreover, GM1 content of human motor nerve myelin is higher than that of sensory nerve myelin [54] . Corbo and co-workers [18] have shown that human anti-GM1 antibodies bind to anterior horn cells, but not to dorsal root ganglion cells. Possibly, increased binding of anti-GM1 antibodies to anterior horn cells, and/or the nodes of Ranvier of motor fibres, accounts for the predominant motor fibre involvement in MMN. It should be noted, however, that there is also evidence for anti-GM1 antibody binding to nodes of Ranvier of sensory fibres [70] .
Treatment (Table 3)
Several treatments directed at the immune system have been tried in MMN. The effects of treatment with prednisone, plasmapheresis, cyclophosphamide and human immunoglobulin (HIG) have been examined. Unfortunately, most studies included limited numbers of patients, making evaluation of treatment efficacy difficult. Moreover, only two blinded placebo-controlled studies have been conducted so far [5, 85] . Table 3 summarizes the results of the studies with larger numbers of MMN patients.
Prolonged prednisone treatment has been tried in several studies without apparent beneficial effect [27, 39, 62, 76] . Donaghy et al. [24] reported rapid deterioration of muscle strength within several weeks in all four MMN patients they treated with prednisone (60 mg/day, 4 weeks), whereas improvement was noted in six out of eight CIDP patients under the same treatment regimen. Plasmapheresis had no beneficial effects on MMN [27, 34, 39, 62] .
Patients who received intravenous cyclophosphamide in a dosage of 0.6 g/m 2 per day for 5 days, followed by oral maintenance therapy up to 10 months at a dose of 50-150 mg/day showed functional improvement associated with a reduction in anti-GM1 titres after several months of treatment [27, 62, 76] . The magnitude of the response varied from almost full functional recovery to a limited increase in muscle strength. This variation may be due to differences in treatment duration and time of assessment. Patients with amyotrophic lateral sclerosis and a "lower motor syndrome" without MCB did not respond to cyclophosphamide [76] .
Promising results with HIG therapy in Guillain Barré syndrome and CIDP [20, 87, 88] have prompted trials of HIG in MMN. MMN patients respond to HIG within hours to days after the first infusion [5, 13, 17] . The degree of improvement varied from an increase in muscle power to achievement of near-normal function in "previously disabled" patients [5, 45, 52, 85] . Again different time spans of the studies may be a source of variation. Clinical improvement was not associated with a consistent decrease of anti-GM1 antibody titres [13, 17, 52, 85] , and is not invariably accompanied by an reduction of MCBs [5, 45, 52, 85] . The duration of improvement typically lasts 1-2 months. Therefore, in order to maintain their functional level, patients have to be treated with HIG on a regular basis. Nobile-Orazio et al. [52] reported that the addition of oral cyclophosphamide (1.5-3 mg/kg per day) permitted a progressive reduction in the frequency of the maintenance HIG infusions. The rapid response to HIG treatment suggests that improvement may not be solely due to structural remyelination of demyelinated fibres. It has been hypothesised that HIG alters the immune balance [37, 89] and allows functional recovery of the nerve, perhaps by unblocking of the sodium channels at the nodes of Ranvier [13] .
One case report has questioned the long-term efficacy of HIG in MMN [26] . A patient who initially benefited from HIG infusions showed progression of the disease that failed to respond to HIG after 1 year of treatment. This report is in disagreement with the finding of longterm improvement by others [45, 52, 84] . In a recent study 19 MMN patients treated with HIG were followed up for at least 2 years and evaluated every 3 months [9] . Two patients showed no response to HIG. Six patients had a very good initial response that lasted more than 6 months. The remaining 11 patients had an initial good response to HIG that did not last more than 6 months. It was observed that of the 6 patients with a lasting response only 1 had substantial muscular atrophy, whereas atrophy was present in 10 of the 11 patients who did not show a sustained response. It was suggested that the degree of atrophy might be predictive for the final treatment outcome. In our experience, long-term HIG maintenance therapy is effective, but frequent (weekly) infusions are necessary to maintain minimal improvement [93] .
As stated previously in this paper, anti-GM1 antibodies have been found in patients with MMN as well as in patients with LMND without conduction block. So far, little is known about the predictive value of anti-GM1 antibodies in identifying a treatable disorder. Pestronk et al. [64] reported four patients with LMND and high-titre serum IgM anti-GM1 antibodies who improved following monthly plasma exchange and intravenous cyclophosphamide treatment. In another study, however, no improvement of muscle strength was found after treatment with prednisone or cyclophosphamide [76] . We treated five patients with LMND associated with high-titre serum IgM anti-GM1 antibodies with HIG. Only one patient responded to the HIG treatment initially, but during maintenance HIG treatment muscle strength gradually declined below pretreatment levels [86] . It can be concluded that in patients with LMND associated with high-titre serum IgM anti-GM1 antibodies the possible benefit of treatment with immunomodulatory drugs is limited as compared with MMN. Cyclophosphamide; IV 0.6 g/m 2 per day for 5 days, + followed by 2 mg/kg per day maintenance Tan et al. 1994 [76] 8 Methyl-prednisolone; IV, 1 g/day for 4 days, 
Conclusion
Multifocal motor neuropathy is characterised by progressive, asymmetrical, predominantly distal limb weakness and the presence of persistent motor conduction blocks. Electrophysiological investigations and pathological studies show evidence of demyelination as well as axonal involvement.
In our opinion MMN is a disease entity that can be distinguished from CIDP and MND. The main features that distinguish MMN from these two other disorders have been summarised in Table 2 . Usually these features will enable differentiation between a diagnosis of MMN or of CIDP or LMND. However, in some patients, in particular those with LMND with an asymmetrical distribution of weakness, differentiation from MMN may be more difficult. With regard to the possibility of treatment and to prognosis this differentiation is, however, crucial. In patients who show clinical characteristics that are compatible with a diagnosis of LMND, but also with a diagnosis of MMN, an extensive electrophysiological examination is required to detect MCBs. When this electrophysiological examination fails to identify MCBs and the weakness is progressing a treatment trial with HIG may be considered. Patients with MMN will mostly respond favourably to HIG within days, whereas LMND patients will fail to respond [86] .
MMN patients respond favourably to cyclophosphamide and HIG treatment. However, the long-term effectiveness of HIG and cyclophosphamide treatment of MMN is not yet sufficiently established. Potentially serious side-effects of cyclophosphamide treatment and high costs of repeated HIG infusions stress the necessity of studies of long-term treatment of MMN patients. Finally, it should be emphasised that establishing internationally accepted diagnostic criteria would be of great value for clinical practice and for standardisation of future studies. 
